Advertisement

Topics

Ocugen Initiates Phase 3 Clinical Trial of OCU300 for the Treatment of Ocular Graft Versus Host Disease

21:07 EDT 1 Jul 2018 | Drugs.com

MALVERN, PA, July 2, 2018 -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it has initiated the first of two...

Original Article: Ocugen Initiates Phase 3 Clinical Trial of OCU300 for the Treatment of Ocular Graft Versus Host Disease

NEXT ARTICLE

More From BioPortfolio on "Ocugen Initiates Phase 3 Clinical Trial of OCU300 for the Treatment of Ocular Graft Versus Host Disease"

Advertisement
Quick Search
Advertisement
Advertisement